# Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

> **NCT01368536** · PHASE4 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 975 (actual)

## Conditions studied

- Hypertension
- Stage 2 Hypertension
- Diabetes

## Interventions

- **DRUG:** Valturna
- **DRUG:** Amlodipine
- **DRUG:** Chlorthalidone
- **DRUG:** Placebo of Valturna Tablet
- **DRUG:** Placebo Capsule

## Key facts

- **NCT ID:** NCT01368536
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 975 (ACTUAL)
- **Why stopped:** Based on results from an ALTITUDE study interim analysis, testing aliskiren concomitantly with an ACE inhibitor or ARB, in diabetics with renal impairment
- **Last updated:** 2013-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01368536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01368536, "Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01368536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*